https://majorhealthnews.com/press-releases/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-togetherMajor Health Newsen2026-11-11T15:08:54.085ZNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity https://majorhealthnews.com/press-releases/amgen-announces-positive-phase-3-results-for-dazodalibep-in-sjogrens-diseaseMajor Health Newsen2026-11-11T13:13:57.122ZAMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE https://majorhealthnews.com/press-releases/context-therapeutics-reports-third-quarter-2026-financial-results-and-pipeline-progressMajor Health Newsen2026-11-10T21:39:35.141ZContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress